Evidence map›Paper›PMID 17542646›Full record

ArticlePLoS pathogens2007

Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss.

Cleo G Anastassopoulou, Andre J Marozsan, Alexandre Matet, Amy D Snyder, Eric J Arts, Shawn E Kuhmann, John P Moore

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Article
  3. SHIV fights back to evade destruction by eCD4-Ig but not without suffering debilitating wounds.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  4. CCR5 Inhibitors and HIV-1 Infection.Journal of AIDS and HIV treatment · 2019
    Article
  5. Article
  6. Fitness landscape of the human immunodeficiency virus envelope protein that is targeted by antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Coreceptors and HIV-1 pathogenesis.Current HIV/AIDS reports · 2011
    Review
  19. Clinical use of CCR5 inhibitors in HIV and beyond.Journal of translational medicine · 2011
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Cleo G AnastassopoulouDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, United States of America.
Andre J Marozsan
Alexandre Matet
Amy D Snyder
Eric J Arts
Shawn E Kuhmann
John P Moore
Cornell University · USCase Western Reserve University · US

Funding

SECOND RECEPTORS FOR PRIMATE IMMUNODEFICIENCY VIRUSESR01AI041420 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 1997 to 2015
$7.3M
Impact of HIV-1 Fitness on Disease ProgressionR01AI049170 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI ARTS, ERIC J · 2002 to 2024
$6.8M
IMMUNOLOGY RESEARCH TRAINING PROGRAMT32AI007621 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI CESARMAN, ETHEL · 1999 to 2014
$3.4M
Mechanism of HIV-1 Escape from a CCR5-specific InhibitorF32AI062664 · NIAID · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI KUHMANN, SHAWN EDWARD · 2004 to 2004
$51k
NIAID NIH HHS F32 AI 062664NIAID NIH HHS F32 AI062664NIAID NIH HHS R01 AI041420NIAID NIH HHS R01 AI049170NIAID NIH HHS R01 AI 41420NIAID NIH HHS T32 AI007621NIAID NIH HHS T32 AI 07621
6 · The paper itself

Abstract

Fitness is a parameter used to quantify how well an organism adapts to its environment; in the present study, fitness is a measure of how well strains of human immunodeficiency virus type 1 (HIV-1) replicate in tissue culture. When HIV-1 develops resistance in vitro or in vivo to antiretroviral drugs such as reverse transcriptase or protease inhibitors, its fitness is often impaired. Here, we have investigated whether the development of resistance in vitro to a small molecule CCR5 inhibitor, AD101, has an associated fitness cost. To do this, we developed a growth-competition assay involving dual infections with molecularly cloned viruses that are essentially isogenic outside the env genes under study. Real-time TaqMan quantitative PCR (QPCR) was used to quantify each competing virus individually via probes specific to different, phenotypically silent target sequences engineered within their vif genes. Head-to-head competition assays of env clones derived from the AD101 escape mutant isolate, the inhibitor-sensitive parental virus, and a passage control virus showed that AD101 resistance was not associated with a fitness loss. This observation is consistent with the retention of the resistant phenotype when the escape mutant was cultured for a total of 20 passages in the absence of the selecting compound. Amino acid substitutions in the V3 region of gp120 that confer complete AD101 resistance cause a fitness loss when introduced into an AD101-sensitive, parental clone; however, in the resistant isolate, changes elsewhere in env that occurred prior to the substitutions within V3 appear to compensate for the adverse effect of the V3 changes on replicative capacity. These in vitro studies may have implications for the development and management of resistance to other CCR5 inhibitors that are being evaluated clinically for the treatment of HIV-1 infection.

Indexed as

CCR5 Receptor AntagonistsAdaptation, PhysiologicalAnti-HIV AgentsBase SequenceCells, CulturedDrug Resistance, ViralHIV-1HumansLeukocytes, MononuclearMolecular Sequence DataNiacinamidePiperazinesReceptors, CCR5Virus ReplicationAD 101Anti-HIV AgentsCCR5 Receptor AntagonistsNiacinamidePiperazinesReceptors, CCR5

Identifiers

PMID17542646
PMCPMC1885273
OpenAlexW1989490564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.